Rocakinogene sifuplasmid clinical trials
Also written INO-9012.
How each study uses rocakinogene sifuplasmid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rocakinogene sifuplasmid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 2
Inovio Pharmaceuticals (6) · Geneos Therapeutics (2) · National Cancer Institute (NCI) (1) · Steven Deeks (1)
Often tested with
Tested in the same studies.
WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401 (2) · Electroporation-Mediated Plasmid DNA Vaccine Therapy (1) · HCV DNA Vaccine INO-8000 (1) · INO-6145 (1) · INO-1800 (1) · INO-4201 (1) · INO-4202 (1) · INO-4212 (1)
Studies
Open first, then newest update. How each study uses rocakinogene sifuplasmid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCCRecruitingPhase 2Geneos TherapeuticsNCT07722741Written as INO-9012
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus InfectionActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02772003Written as Rocakinogene Sifuplasmid
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Active, not recruitingPhase 1/2Inovio PharmaceuticalsNCT03491683Written as INO-9012
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCActive, not recruitingPhase 1/2Geneos TherapeuticsNCT04251117Written as INO-9012
- INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaCompletedPhase 1/2Inovio PharmaceuticalsNCT03502785Written as INO-9012
- Therapeutic Vaccination in Treated HIV DiseaseCompletedPhase 1/2Steven DeeksNCT03606213Written as INO-9012
- Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsCompletedPhase 1Inovio PharmaceuticalsNCT02431312Written as INO-9112
- Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersCompletedPhase 1Inovio PharmaceuticalsNCT02464670Written as INO-4212 + INO-9012
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseCompletedPhase 1Inovio PharmaceuticalsNCT02960594Written as INO-9012
- Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesCompletedPhase 1Inovio PharmaceuticalsNCT02241369Written as INO-3106, INO-9012
Given beside what is tested · 3 — rocakinogene sifuplasmid is usual care or a partner of the new treatment
- Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated GlioblastomaActive, not recruitingPhase 1Washington University School of MedicineNCT04015700Written as Plasmid encoded IL-12
- INO 5401 Vaccination in BRCA1/2 Mutation CarriersActive, not recruitingPhase 1University of PennsylvaniaNCT04367675Written as INO-9012
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersWithdrawnPhase 1Inovio PharmaceuticalsNCT05430958Written as INO-9112
Codes
What other systems call rocakinogene sifuplasmid · ClinicalTrials.gg INT001873
- MeSH (NLM) C000722693rocakinogene sifuplasmidConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 91JHE0ANN8ROCAKINOGENE SIFUPLASMIDConfirmed FDA, NLM
- NCI Thesaurus C116709Rocakinogene SifuplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722693 | rocakinogene sifuplasmid | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 91JHE0ANN8 | ROCAKINOGENE SIFUPLASMID | Confirmed FDA, NLM |
| NCI Thesaurus | C116709 | Rocakinogene Sifuplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.